Olaparib

Drug Profile

Olaparib

Alternative Names: AZD-2281; KU-0059436; KU-59436; Lynparza

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator KuDOS Pharmaceuticals
  • Developer AstraZeneca; Cancer Research UK; M. D. Anderson Cancer Center; Massachusetts General Hospital; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phthalazines; Piperazines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Breast cancer; Pancreatic cancer
  • Phase II Prostate cancer; Solid tumours
  • Phase I/II Fallopian tube cancer; Glioblastoma; Head and neck cancer; Peritoneal cancer; Small cell lung cancer
  • No development reported Colorectal cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 13 Jan 2017 AstraZeneca plans a phase I trial in Head and neck cancer (Neoadjuvant treatment) in USA, France and United Kingdom (NCT03022409)
  • 12 Dec 2016 National Cancer Institute plans a phase II trial for Glioblastoma (Combination therapy) in USA (NCT02974621)
  • 06 Dec 2016 AstraZeneca plans the phase III PROfound trial for Prostate cancer (Hormone refractory, Metastatic disease) in USA, Canada, Italy, Taiwan, South Korea, Spain, Australia, Germany, Japan, United Kingdom, France, Argentina, Austria, Brazil, China, Denmark, Israel, Netherlands, Turkey and Norway (PO, Tablet) (NCT02987543)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top